25 related articles for article (PubMed ID: 38687678)
1. Loss of Tumour Suppressor TMEM127 Drives RET-mediated Transformation Through Disrupted Membrane Dynamics.
Walker TJ; Reyes-Alvarez E; Hyndman BD; Sugiyama MG; Oliveira LCB; Rekab AN; Crupi MJF; Cabral-Dias R; Guo Q; Dahia PLM; Richardson DS; Antonescu CN; Mulligan LM
bioRxiv; 2024 Apr; ():. PubMed ID: 37425958
[TBL] [Abstract][Full Text] [Related]
2. TMEM127 suppresses tumor development by promoting RET ubiquitination, positioning, and degradation.
Guo Q; Cheng ZM; Gonzalez-Cantú H; Rotondi M; Huelgas-Morales G; Ethiraj P; Qiu Z; Lefkowitz J; Song W; Landry BN; Lopez H; Estrada-Zuniga CM; Goyal S; Khan MA; Walker TJ; Wang E; Li F; Ding Y; Mulligan LM; Aguiar RCT; Dahia PLM
Cell Rep; 2023 Sep; 42(9):113070. PubMed ID: 37659079
[TBL] [Abstract][Full Text] [Related]
3. Functional Characterization of TMEM127 Variants Reveals Novel Insights into Its Membrane Topology and Trafficking.
Flores SK; Deng Y; Cheng Z; Zhang X; Tao S; Saliba A; Chu I; Burnichon N; Gimenez-Roqueplo AP; Wang E; Aguiar RCT; Dahia PLM
J Clin Endocrinol Metab; 2020 Sep; 105(9):e3142-56. PubMed ID: 32575117
[TBL] [Abstract][Full Text] [Related]
4. The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo.
Oliveira MN; Hemerly JP; Bastos AU; Tamanaha R; Latini FR; Camacho CP; Impellizzeri A; Maciel RM; Cerutti JM
Thyroid; 2011 Sep; 21(9):975-85. PubMed ID: 21834681
[TBL] [Abstract][Full Text] [Related]
5. The TMEM127 human tumor suppressor is a component of the mTORC1 lysosomal nutrient-sensing complex.
Deng Y; Qin Y; Srikantan S; Luo A; Cheng ZM; Flores SK; Vogel KS; Wang E; Dahia PLM
Hum Mol Genet; 2018 May; 27(10):1794-1808. PubMed ID: 29547888
[TBL] [Abstract][Full Text] [Related]
6. Loss of tumor suppressor TMEM127 drives RET-mediated transformation through disrupted membrane dynamics.
Walker TJ; Reyes-Alvarez E; Hyndman BD; Sugiyama MG; Oliveira LCB; Rekab AN; Crupi MJF; Cabral-Dias R; Guo Q; Dahia PLM; Richardson DS; Antonescu CN; Mulligan LM
Elife; 2024 Apr; 12():. PubMed ID: 38687678
[TBL] [Abstract][Full Text] [Related]
7. Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function.
Mukherjee S; Tessema M; Wandinger-Ness A
Circ Res; 2006 Mar; 98(6):743-56. PubMed ID: 16574915
[TBL] [Abstract][Full Text] [Related]
8. Genetics and molecular pathogenesis of pheochromocytoma and paraganglioma.
Galan SR; Kann PH
Clin Endocrinol (Oxf); 2013 Feb; 78(2):165-75. PubMed ID: 23061808
[TBL] [Abstract][Full Text] [Related]
9. [Hereditary pheochromocytoma-associated syndromes. Part 1].
Yukina MY; Troshina EA; Beltsevich DG
Ter Arkh; 2015; 87(9):102-105. PubMed ID: 26591561
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of receptor trafficking in tumorigenicity.
Parachoniak CA; Park M
Trends Cell Biol; 2012 May; 22(5):231-40. PubMed ID: 22397948
[TBL] [Abstract][Full Text] [Related]
11. Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options.
Vicha A; Musil Z; Pacak K
Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):186-91. PubMed ID: 23481210
[TBL] [Abstract][Full Text] [Related]
12. RET and neuroendocrine tumors.
Murakumo Y; Jijiwa M; Asai N; Ichihara M; Takahashi M
Pituitary; 2006; 9(3):179-92. PubMed ID: 17036197
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
